Lung function improvement on triple modulators: high-resolution, nationwide data from the Danish Cystic Fibrosis Cohort.

Background: People living with cystic fibrosis in Denmark had early, universal access to triple modulator treatment with elexacaftor/tezacaftor/ivacaftor. Close monitoring allowed us to assess the impact of treatment on lung function and progression of lung disease in an unselected nationwide cystic fibrosis population from 6 years of age.

Methods: Data were analysed using linear mixed-effect models to assess changes in levels and annual rates of change (slopes) in percent predicted (pp) forced expiratory volume in 1 s (FEV), forced vital capacity (FVC) and forced expiratory flow at 25-75% of FVC (ppFEF) between the 12 months pre-treatment and treatment periods.

Infrared Spectroscopy of Phase Transitions in the Lowest Landau Levels of Bilayer Graphene.

We perform infrared magnetospectroscopy of Landau level (LL) transitions in dual-gated bilayer graphene. At ν=4 when the zeroth LL (octet) is filled, two resonances are observed indicating the opening of a gap. At ν=0 when the octet is half-filled, multiple resonances disperse nonmonotonically with increasing displacement field, D, perpendicular to the sheet, showing a phase transition at modest displacement fields from a canted antiferromagnet (CAFM) to the layer-polarized state, with a gap that opens linearly in D.

Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis.

Sweat chloride concentration, a diagnostic feature in cystic fibrosis (CF), reflects CF transmembrane conductance regulator (CFTR) activity. CFTR modulator therapies, especially elexacaftor/tezacaftor/ivacaftor (ETI), has improved CF outcomes. We report nationwide, real-world data on sweat chloride concentration in people with CF (pwCF) with and without modulator therapies.

Improved early growth in Danish children with cystic fibrosis from 2000-2022.

Background: Improved growth in children with CF may have resulted from advances in treatment for cystic fibrosis (CF) over the past two decades, including the implementation of newborn screening in Denmark in 2016. This observational cohort study focuses on changes in early growth in Danish children with CF born between 2000 and January 2022.

Methods: Age, length/height, and weight data of children 0-5 years old were obtained from the Danish CF Cohort.

Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and meta-analysis.

Background: Considering the persistent nature and higher prevalence of insomnia in cancer patients and survivors compared with the general population, there is a need for effective management strategies. This systematic review and meta-analysis aimed to comprehensively evaluate the available evidence for the efficacy of pharmacological and nonpharmacological interventions for insomnia in adult cancer patients and survivors.

Methods: Following the PRISMA guidelines, we analyzed data from 61 randomized controlled trials involving 6528 participants.